Compare HOV & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOV | BWAY |
|---|---|---|
| Founded | 1959 | 2003 |
| Country | United States | Israel |
| Employees | 1891 | 129 |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 646.9M | 674.2M |
| IPO Year | N/A | N/A |
| Metric | HOV | BWAY |
|---|---|---|
| Price | $100.33 | $16.44 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $97.00 | $13.25 |
| AVG Volume (30 Days) | 91.0K | ★ 131.1K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $309.69 |
| Revenue Next Year | $5.96 | $26.21 |
| P/E Ratio | ★ $17.50 | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $85.69 | $8.61 |
| 52 Week High | $162.06 | $26.63 |
| Indicator | HOV | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 35.90 | 56.96 |
| Support Level | $100.24 | $14.56 |
| Resistance Level | $113.60 | $16.63 |
| Average True Range (ATR) | 5.82 | 0.62 |
| MACD | -1.20 | 0.22 |
| Stochastic Oscillator | 4.68 | 71.03 |
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations. The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments: Northeast, which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia; Southeast, which includes Florida, Georgia, and South Carolina; and West, which includes Arizona, California, and Texas. The firm generates maximum revenue from the West Segment.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.